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RR19.
A Longitudinal Comparison of Endovascular and
Open Surgical Management of Popliteal Artery Aneu-
rysms in the US Medicare Population
Todd R. Vogel, Paul L. O’Donnell, Viktor Y. Dombrovs-
kiy, Alan M. Graham. Department of Surgery, UMDNJ-
Robert Wood Johnson Medical School, New Brunswick,
NJ
Objectives: The treatment of popliteal artery aneu-
rysms has undergone significant transition from open
surgery to endovascular graft placement. Despite this
dramatic change, few longitudinal data exist evaluating
outcomes. (Methods: The Centers of Medicare & Medicaid Ser-
ices Inpatient claims (2005-2007) were queried with a
rincipal diagnosis of lower extremity artery aneurysm in
ssociation with elective CPT codes for open (OPEN) and
ndovascular (ENDO) repair of popliteal artery aneurysms.
omplications, mortality, readmission, and re-interven-
ions were evaluated.
Results: 2,962 patients were identified. The fre-
uency of endovascular interventions increased from
1.7% to 23.6% (p  .0001). The overall complication
ates after OPEN (11.3%) and ENDO (9.3%) procedures
id not differ significantly (p0.17). Cardiac, pulmo-
ary, and infectious complications were more frequent
fter OPEN whereas hemorrhagic complications oc-
urred more frequently after ENDO. No significant dif-
erences in the 30- and 90-day mortality rates were found
etween OPEN vs. ENDO. Secondary re-interventions
or ENDO were greater at both 30 days (4.6%vs.2.1%;
.001) and 90 days (11.8%vs.7.4%;p0.0007). Embolec-
omy and thrombolysis rates over time were significantly
igher after ENDO at 30 days (1.82%vs.0.46%,p.0006 and
.46%vs.0.25%,p0.0002) and 90 days (2.73%vs.0.75%,
.0002 and 3.28%vs.0.75%,p0.0002). The length of
tay (days) was greater for OPEN (4.5vs.2.5,p .0001), yet
otal hospital charges were greater for ENDO ($43,180
s.$35,540,p.0001).
Conclusions: Despite a significant increase in endovas-
ular repair of popliteal artery aneurysms in the US Medi-
are population, endovascular repair was associated with
reater re-interventions over time. Although endovascular
epair had shorter lengths of stay and is considered less
nvasive, it did not offer a mortality or cost benefit. Further
etailed analysis is needed before endovascular repair
hould be considered the treatment of choice for popliteal
neurysms.
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ltrasound-Accelerated Thrombolysis is Superior to
atheter-Directed Thrombolysis for the Treatment of
cute Limb Ischemia
aria E. Litzendorf, Jean E. Starr, Bhagwan Satiani, Kath-
rine E. Notter. Ohio State University, Columbus, OH
Objectives: Ultrasound-accelerated thrombolysis has
ecome an alternative to traditional catheter-directed
hrombolysis for the treatment of acute limb ischemia. The
urpose of this study was to compare outcomes and hospi-
al costs for these two treatments.
Methods: A hospital record review was performed of
ll patients treated with catheter-directed thrombolysis
non-EKOS) versus ultrasound-accelerated thrombolysis
EKOS) from January 2007 through December 2009.
